Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus by De Iaco, Alberto & Luban, Jeremy
RESEARCH Open Access
Inhibition of HIV-1 infection by TNPO3 depletion
is determined by capsid and detectable after viral
cDNA enters the nucleus
Alberto De Iaco and Jeremy Luban
*
Abstract
Background: HIV-1 infects non-dividing cells. This implies that the virus traverses the nuclear pore before it
integrates into chromosomal DNA. Recent studies demonstrated that TNPO3 is required for full infectivity of HIV-1.
The fact that TNPO3 is a karyopherin suggests that it acts by directly promoting nuclear entry of HIV-1. Some
studies support this hypothesis, while others have failed to do so. Additionally, some studies suggest that TNPO3
acts via HIV-1 Integrase (IN), and others indicate that it acts via capsid (CA).
Results: To shed light on the mechanism by which TNPO3 contributes to HIV-1 infection we engineered a panel
of twenty-seven single-cycle HIV-1 vectors each bearing a different CA mutation and characterized them for the
ability to transduce cells in which TNPO3 had been knocked down (KD). Fourteen CA mutants were relatively
TNPO3-independent, as compared to wild-type (WT) HIV-1. Two mutants were more TNPO3-dependent than the
WT, and eleven mutants were actually inhibited by TNPO3. The efficiency of the synthesis of viral cDNA, 2-LTR
circles, and proviral DNA was then assessed for WT HIV-1 and three select CA mutants. Controls included rescue of
TNPO3 KD with non-targetable coding sequence, RT- and IN- mutant viruses, and pharmacologic inhibitors of RT
and IN. TNPO3 KD blocked transduction and establishment of proviral DNA by wild-type HIV-1 with no significant
effect on the level of 2-LTR circles. PCR results were confirmed by achieving TNPO3 KD using two different
methodologies (lentiviral vector and siRNA oligonucleotide transfection); by challenging three different cell types;
by using two different challenge viruses, each necessitating different sets of PCR primers; and by pseudotyping
virus with VSV G or using HIV-1 Env.
Conclusion: TNPO3 promotes HIV-1 infectivity at a step in the virus life cycle that is detectable after the
preintegration complex arrives in the nucleus and CA is the viral determinant for TNPO3 dependence.
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Background
Upon fusing with a target cell membrane, retroviruses
release the virion core into the target cell cytoplasm.
The core consists of a capsid (CA) protein lattice within
which are located the viral genomic RNA, reverse tran-
scriptase (RT), and integrase (IN), among other viral
components. RT generates double-stranded DNA using
the viral genomic RNA as template, though the exact
intracellular location of these reactions, or the structural
transformations undergone by the core, are not clear.
Recent studies indicate that the CA disassembles
(uncoats) in response to reverse transcription [1]. The
resulting pre-integration complex (PIC) minimally bears
IN and viral cDNA. Immunofluorescence microscopy
studies indicate that CA remains associated with a viral
structure, perhaps the PIC, that contains the nascent
viral cDNA [2] and docks to the nuclear pore [3]. The
PIC then gains access to the host nucleus, where IN
ligates the viral cDNA into host chromosomal DNA,
establishing the provirus. Genetic experiments indicate
that CA is critically important for these early steps in
the infection cycle that culminate in integration [4-7].
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the retroviral replication cycle, not every PIC reaching
the nucleus integrates into host cell chromosomal DNA
[8]. The termini of the retroviral DNA are recognized
by host nuclear factors that join them to produce circu-
lar DNAs, which are unable to integrate. Two covalently
closed circular forms of retroviral DNA can be found in
the nucleus: 1-LTR circles produced by recombination
of the long-terminal repeats (LTRs) or 2-LTR circles
produced by joining the LTR termini [8,9]. Unlike the
permanent provirus, the circular forms are transient,
though in some cases they are transcribed and direct
protein synthesis [10,11]. Nonetheless, LTR circles pro-
v i d eav a l u a b l ei n d i c a t i o n that the viral cDNA has
arrived within the nucleus [12].
The mechanism by which retroviruses gain access to
the nucleus is not the same for all retrovirus genera.
Lentiviruses such as human immunodeficiency virus
type 1 (HIV-1) infect non-dividing cells [13-16], indicat-
ing that the lentivirus PIC traverses the nuclear pore. In
contrast, mitosis is required for integration by gammare-
troviruses like murine leukemia virus (MLV) [15,17].
T h eH I V - 1P I Ci sa tl e a s t~ 5 6n m[ 1 8 ]a n dt h e r e f o r e
exceeds the 9 nM size-exclusion limit for passive diffu-
sion through the channel of the nuclear pore complex
(NPC) [19]. To enter the nucleus then, the PIC likely
depends upon an active transport mechanism. Many
groups have attempted to determine which viral and cel-
lular factors promote nuclear import of the HIV-1 PIC.
Matrix protein (MA) [20], Viral protein R (Vpr) [21], IN
[22] and the DNA flap [23] have all been proposed as
viral determinants for nuclear entry of the PIC. Experi-
ments using chimeric retroviruses in which HIV-1 CA
was replaced with MLV CA, pinpointed CA as a viral
determinant for infection of nondividing cells [24].
Moreover, specific CA mutants confer a defect in the
ability of HIV-1 to infect nondividing cells [4]. From the
standpoint of cellular factors, importin-a [21], importin-
b [25,26], importin-7 [27] and transportin-SR2 (TNPO3)
[26,28,29], as well as the NPC components NUP153 and
NUP358 [26,29-31], have all been implicated in HIV-1
nuclear transport.
TNPO3 is an importin-b-like karyopherin that pro-
motes the nuclear import of serine/arginine-rich splicing
factors (SR proteins) [32]. Two genome-wide siRNA
screens demonstrated the importance of TNPO3 for
HIV-1 replication, and showed that TNPO3 acts early in
infection, but after reverse transcription [26,29]. TNPO3
was also identified in a two-hybrid screen for proteins
that interact with HIV-1 IN [28], suggesting that
TNPO3 promotes nuclear import of the PIC via direct
interaction with the IN protein. On the other hand,
exploiting the fact that MLV is TNPO3-independent
[28], experiments with HIV-1/MLV chimeric viruses
mapped the requirement for TNPO3 to CA, not IN
[33], and HIV-1 CA mutants have been identified that
are TNPO3-independent [6,34]
By examining the effect of TNPO3 on the formation
of 2-LTR circles, some studies have suggested that
TNPO3 promotes nuclear transport of the HIV-1 PIC,
while others have not. The first report on the effect of
TNPO3 KD on HIV-1 replication [26] showed a block
to provirus formation in TNPO3 KD cells, but omitted
experiments showing the level of 2-LTR circles. Two
studies reported a decrease in 2-LTR circles in the face
of TNPO3 KD [28,35], while two others showed no
effect [29,34]. To clarify at which step TNPO3 acts in
the HIV-1 life cycle, we examined the fate of viral
cDNA under a variety of conditions in cells depleted of
TNPO3.
Results
TNPO3 knockdown and rescue with non-targetable
TNPO3 cDNA
To examine the role of TNPO3 in HIV-1 infection, len-
tiviral vectors were used to generate a panel of HeLa
cells with TNPO3 knockdown (KD) and optimal con-
trols (Figure 1A-C). A first round of transduction was
conducted with lentiviral KD vectors that encode miR30
microRNAs (miRNAs) engineered to target either
TNPO3 mRNA, or firefly luciferase as a control (Figure
1A). The same miRNA-containing, primary transcript of
these vectors encodes puromycin N-acetyltransferase
[36], so pools of transduced cells were selected in the
presence of puromycin. Each of the two pools of KD
cells were then transduced a second time with a rescue
lentivector expressing a TNPO3 cDNA (ntTNPO3) that
bears silent mutations so that it is predicted to be resis-
tant to KD (Figure 1A). The empty version of this vector
served as a control. The rescue vector expressed a blas-
ticidin-resistance cassette under the translational control
of the encephalomyocarditis virus (EMCV) internal ribo-
some entry site (IRES). A second round of selection
with blasticidin was applied to obtain four pools of cells,
each of which was resistant to both puromycin and blas-
ticidin (Figure 1B).
The KD and rescue of TNPO3 in the four pools of
cells was verified by western blot (Figure 1C). If any-
thing, the steady-state level of TNPO3 protein in the
rescue cells was higher than the endogenous TNPO3 in
the starting population of HeLa cells. These four pools
of modified HeLa cells were then used for subsequent
experiments concerning the effects of TNPO3 on HIV-1
transduction.
Effect of HIV-1 CA mutants on TNPO3-dependence
Since previous studies suggest that CA is the viral deter-
minant for HIV-1 replication-dependence on TNPO3
De Iaco and Luban Retrovirology 2011, 8:98
http://www.retrovirology.com/content/8/1/98
Page 2 of 19Figure 1 TNPO3 depletion and rescue with non-targetable TNPO3 cDNA. (A) Schematic representation of the lentiviral vectors used to
generate TNPO3 knockdown (KD) and rescue cell lines. (B) The sequence of steps used to obtain the four pools of stable cell lines. HeLa cells
were transduced with control (Ctrl) KD vector or with TNPO3 KD vector, and selected in pools with 10 μg/ml of puromycin. Each pool of KD
cells was then transduced a second time with the rescue vector, either empty or bearing non-targetable TNPO3 cDNA (ntTNPO3), and selected
in pools with 10 μg/ml of blasticidin, as well as 1 μg/ml puromycin. (C) Steady-state levels of TNPO3 protein in each of the four pools of
doubly-tranduced cells. Cell lysate was probed in western blots with anti-TNPO3 antibody (upper panel) and anti-b-actin antibody (lower panel).
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Page 3 of 19[6,33,34], the infectivity of a panel of 27 HIV-1 CA
mutants was compared to that of the wild type (WT), in
the context of TNPO3 KD (Figure 2). The CA mutants
that were tested here were selected based on previously
described phenotypes (Table 1): G89V, P90A, and
V86P/H87Q/I91V/M96I are cyclophilin A (CypA)-inde-
pendent [37-39]; E45A, T54A, T54A/N57A, Q63A/
Q67A, K70A, A92E, G94D, and R132K are defective for
transduction of cells arrested in the cell-cycle [4,40,41];
E45A, T54A, A92E, and R132K are cyclosporin A
(CsA)-dependent [41,42]; G89V, P90A, and A105T each
complement the infectivity of CsA-dependent mutants
[41,43]; E45A makes a hyper-stable core [44]; T54A,
T54A/N57A, and Q63A/Q67A make unstable cores
[4,45,46]; E45A, T54A, T54A/N57A, Q63A/Q67A, and
N74D have been reported to be TNPO3-independent
[6,34]; N74D and P90A are Nup153-independent [30].
TNPO3 KD and luciferase (Ctrl) KD HeLa cells were
challenged with three-part lentiviral vectors encoding a
GFP reporter gene and pseudotyped with VSV Glyco-
protein (VSV G). Individual vectors bearing each of the
CA mutants were compared side-by-side with the WT
CA. Three days after challenge with the vectors the
extent of transduction was determined by assessing the
percent GFP
+ cells by flow cytometry. As compared to
the control KD cells, transduction of the TNPO3 KD
cells by WT HIV-1 was 11-fold lower (Figure 2). CA
mutants G89V/A92E and P90A/A92E were significantly
more sensitive to TNPO3 depletion than the WT (Fig-
u r e2 ,p<0 . 0 1 ) .T r a n s d u c t i o nb yf o u r t e e no ft h eC A
mutants was relatively independent of TNPO3 (Figure 2,
p < 0.01). For eleven of the mutants, most prominently
E45A, T54A/N57A, Q63A/Q67A, and N74D/A105T,
TNPO3 KD increased infectivity from 2 to 4-fold (Fig-
ure 2), indicating that TNPO3 inhibits transduction by
these viruses. The analysis with this large panel of CA
mutants demonstrates that CA is the primary viral
determinant for HIV-1 dependence upon TNPO3.
TNPO3-independent CA mutants cluster on the surface of
the CA lattice
When absolute infectivity relative to WT virus was con-
sidered, the TNPO3-independent CA mutants clustered
into two groups. N74D, A105T, and most double-
mutants involving these residues had absolute infectivity
as high as the WT (Figure 3A, purple bars). For E45A,
T54A/N57A, Q63A/Q67A, K70A, G89V, R132K, K140R,
and K182R, absolute infectivity was reduced as com-
pared with the WT (Figure 3A, dark blue bars).
When viewed on a structural model for the hexameric
CA lattice (PDB file #3H4E), the location of most of the
CA residues that, when mutated, render HIV-1 TNPO3-
independent, is near the point of contact between two
CA monomers in the CA hexamer. Figure 3B shows the
interface between two CA monomers in isolation from
the rest of the CA hexamer model. E45, T54, N57, Q63,
Q67, K70, K140 and K182 localize to the actual CA
dimer interface. Mutants at these positions have been
reported to alter CA stability [4,44-46], a phenotype that
may explain the decreased absolute infectivity of these
mutants. Amino acids N74 and A105 are located within
a pocket adjacent to the CA dimer interface that has
been targeted for the development of small molecule
inhibitors of HIV-1. One such molecule, PF-3450074
(PF74), destabilizes the CA core [47]. It is interesting
that the absolute infectivity for these two TNPO3-inde-
pendent mutants is not decreased.
Detailed analysis of selected CA mutants exhibiting
TNPO3 phenotypes with minimal fitness cost
Having screened the panel of 27 CA mutants, three
mutants with TNPO3 phenotypes, but good absolute
infectivity, were selected for more detailed characteriza-
tion. Each of the four pools of TNPO3 KD and rescue
cells described above (Figure 1) were challenged with
WT, P90A/A92E, N74D, and A105T CA mutant viruses.
Infectivity with virus bearing WT CA was 10-fold lower
in TNPO3 KD cells than in Luciferase KD control cells
(Figure 4). This defect increased to nearly 15-fold with
the P90A/A92E CA mutant virus (p < 0.01). When the
ntTNPO3 rescue cells were used as targets, the infectiv-
ity of the WT and P90A/A92E viruses was restored to
control levels. This indicates that the defect in transduc-
tion efficiency by these viruses was due to reduction in
TNPO3, and not to off-target effects. In contrast to
what was observed with the WT and P90A/A92E
viruses, the infectivity of N74D or A105T CA mutant
viruses was not decreased by TNPO3 KD (Figure 4).
When TNPO3 KD and rescue CD4
+-HeLa cells were
challenged with the same CA mutants in the context of
HIV-1 reporter virus bearing the HIV-1 Env glycopro-
tein, the results were identical to those obtained with
VSV G-pseudotyped vector (data not shown).
The effect of TNPO3 knockdown on HIV-1 replication is
detectable after the virus reaches the nucleus
Previous studies concur that TNPO3 depletion results in
a block to HIV-1 replication that occurs after reverse
transcription has been completed, but before establish-
ment of the provirus [26,28,29,34]. There is disagree-
ment, though, about whether TNPO3 KD changes the
levels of the HIV-1 circular cDNAs that serve as a mar-
ker for arrival of the viral cDNA into the nucleus
[28,29,34,35].
The fate of the HIV-1 genome during the early phases
of infection in the TNPO3-KD and rescue HeLa cells
was examined next using quantitative PCR (qPCR). As
described above, TNPO3 levels in these cells had been
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Page 4 of 19Figure 2 The effect of TNPO3 KD on the infectivity of HIV-1 CA mutants in HeLa cells. HeLa control (ctrl) KD cells and TNPO3 KD cells
were challenged with a panel of 27 HIV-1-GFP reporter vectors bearing either WT CA or the indicated CA mutants. At 72 hrs the percent GFP
+
cells was determined by flow cytometry as an indication of infectivity. The ratio of HIV-1 infectivity in Ctrl KD vs TNPO3 KD cells is shown. Error
bars represent ± SEM (n = 3). Black bars indicate mutants that were significantly less sensitive than the WT to TNPO3 KD (p < 0.01, t-test). Gray
bars indicate mutants that were significantly more sensitive than the WT to TNPO3 KD (p < 0.01, t-test).
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Page 5 of 19modified by sequential transduction with two different
HIV-1 vectors, one for TNPO3 knockdown and one for
rescue with ntTNPO3 cDNA (Figure 1). To circumvent
the signal that would be generated by these proviruses
in PCR reactions using conventional primers to HIV-1
sequences, cells were challenged with pWPTs-GFP, a
vector that carries an engineered, 34-nucleotide loxP site
i nt h eU 3r e g i o no ft h e3 ’LTR. PCR reactions using a
primer complementary to the loxP s i t ew e r ea b l et od i s -
tinguish pWPTs-GFP-derived signals from those of the
two proviruses that were already present in these cells
(Figure 5). Cells were challenged for 24 hrs with WT or
CA mutant viruses and DNA was extracted. Each sam-
ple was subjected to qPCR to assess the amount of late
RT products (Figure 6A), 2-LTR circles (Figure 6B), and
proviral DNA (Figure 6C). Isogenic HIV-1 viruses bear-
ing previously characterized, inactivating mutations in
the catalytic site of RT (D185K/D186K) [48] or in the
catalytic site of IN (D116A) [49] were used as controls
for the qPCR reactions.
TNPO3 KD had no clear effect on the yield of full-
length viral cDNA for any of the viruses tested (Figure
6A). cDNA synthesis by RT mutant D185K/D186K was
severely compromised, indicating that the signals
observed with the other viruses resulted from de novo
cDNA synthesis, not from contamination with plasmid
DNA used to produce the virus stocks. Similarly,
TNPO3 depletion had no detectable effect on the
amount of 2-LTR circles formed during infection with
WT or CA mutant virus (Figure 6B). The identity of the
2-LTR circles produced by the WT and by each of the
mutants was confirmed by sequencing. Finally, TNPO3
KD blocked provirus formation by WT and P90A/A92E
mutant viruses (Figure 6C). The magnitude of the
defect, 8-fold and 12-fold, respectively, was similar to
that of the block in infectivity (compare with Figure
4A). The N74D and A105T mutant viruses, on the
other hand, established proviruses independently of
TNPO3 (Figure 6C). Provirus formation by the IN
mutant D116A was at the level of the background,
indicating that a detectable signal in the Alu-PCR reac-
tion requires IN with endonuclease activity.
TNPO3 KD by transfection of siRNA
To determine if differences in methodology might
explain discrepancies between the results reported here
and those reported by some other groups [28,35],
TNPO3 KD was attempted by transfection of dsRNA
oligonucleotides. Reduction in TNPO3 protein in cells
transfected with TNPO3-specific siRNA, as compared
with cells transfected with the siRNA control, was evi-
dent by western blot (Figure 7A). Then, rather than
challenge the KD cells with a three-part HIV-1 vector as
in the previous experiments, a two-part, VSV G-pseudo-
typed, pNL4-3-GFP reporter virus was used here. As
compared with the cells transfected with the control
siRNA, infection of the TNPO3 depleted cells with the
pNL4-3-GFP reporter virus was reduced 15-fold (Figure
7B).
Since TNPO3 KD in these cells was accomplished
without lentiviral KD vectors, and the challenge virus
was an unmodified pNL4-3 that did not possess loxP
sites, viral cDNA was amplified in qPCR reactions using
conventional primers specific for the HIV-1 sequence
[50]. As in the previous experiment in Figure 6, TNPO3
KD had no detectable effect on reverse transcription
(Figure 7C), or on 2-LTR circle formation (Figure 7D),
but provirus formation was severely compromised (Fig-
ure 7E). A strong block to integration can be associated
with an increased accumulation of DNA circles [29].
TNPO3 KD was indeed associated with a 30% increase
in 2-LTR circles, as compared with an 80% increase in
the presence of the IN strand-transfer inhibitor Ralte-
gravir. The products in these qPCR experiments were
detected with SYBR green but identical results were
obtained when products were detected with TaqMan
probes (data not shown), as previously described [50].
Taken together, these results indicate that the block to
HIV-1 replication in the face of TNPO3 KD is detect-
able after the virus reaches the nucleus.
Table 1 Phenotypes reported for the CA mutants tested in this study.
Phenotypes CA mutants References
CypA-independent G89V, P90A, V86P/H87Q/I91V/M96I [37-39]
Defective for transduction of cells arrested in the cell-cycle E45A, T54A, T54A/N57A, Q63A/Q67A, K70A, A92E, G94D, R132K [4,40,41]
CsA-dependent E45A, T54A, A92E, G94D, R132K [41,42]
Complementing the infectivity of CsA-dependent mutants G89V, P90A, A105T [41,43]
Hyper-stable core E45A [44]
Unstable core T54A, T54A/N57A, Q63A/Q67A [4,45,46]
TNPO3-independent E45A, T54A, T54A/N57A, Q63A/Q67A, N74D, A105S [6,34]
Nup153-independent N74D, P90A [30]
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Page 6 of 19Figure 3 HIV-1 CA mutants that confer TNPO3-independence localize to the interface between two monomers in the hexameric CA
lattice. (A) Absolute infectivity relative to WT virus of TNPO3-independent CA mutants. Data represent one of at least three independent
experiments. Error bars represent ± SEM (n = 3). (B) Location of CA amino acid residues important for TNPO3-dependence of HIV-1. Space-fill
model of a CA dimer extracted from the hexameric structure (PDB: 3H4E). The location of mutants with absolute infectivity similar WT is
indicated in magenta. The location of mutants with an absolute infectivity defect are shown in blue; Q63 is in the dimer interface and not visible
in this view.
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Page 7 of 19Figure 4 Infectivity of HIV-1-GFP vectors carrying WT or mutant CA on KD and rescue HeLa cells. Expression of the GFP reporter gene
was checked by flow cytometry 72 hrs after challenge with virus. Infectivity relative to WT is shown in (A). The ratio of the infectivity in TNPO3
KD compared to the control KD cells is shown in (B). Data represent one of at least three independent experiments. Error bars represent ± SEM
(n = 3).
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Page 8 of 19Figure 5 Strategy for detecting cDNA from HIV-1 reporter virus after challenge of cells that had been previously transduced with HIV-
1-based, lentivirus KD and rescue vectors. Schematic diagram showing methods of detection for HIV-1 late RT products (A), 2-LTR circles (B)
and provirus (C) in KD cell lines. Identification of nascent cDNA is made possible by the presence of a loxP sequence engineered within a region
of the 3’LTR U3 that is dispensable for retrotransposition.
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Page 9 of 19Figure 6 Effect of TNPO3 on the de novo synthesis and fate of HIV-1 cDNA after acute infection. WT or CA mutant HIV-1 reporter virus
were used to challenge the TNPO3 KD and rescue cells, as indicated. 24 hrs later, late RT (A), 2-LTR circles (B) and provirus (C) were assayed by
qPCR. Viruses bearing the enzymatic site mutants RT-D185K/D186L or IN-D116A IN were used as controls for de novo reverse transcription and
integration, respectively. Data represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
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Page 10 of 19The effect of TNPO3 KD on HIV-1 transduction of CD4
+ T
cells
In the previous experiments, the effect of TNPO3 deple-
tion was assessed using HeLa cervical cancer cells. Iden-
tical results were obtained when the lentiviral KD and
rescue vectors were used in TE671 cells (data not
shown). Since CD4
+ T lymphocytes are the primary cel-
lular target of HIV-1, TNPO3 KD Jurkat T cells were
also generated with the lentiviral KD vectors. Infectivity
with virus bearing WT CA was 5-fold lower in TNPO3
KD cells than in control KD cells (Figure 8A). P90A/
A92E CA mutant virus showed higher inhibition
Figure 7 Effect of TNPO3 KD by transfection of siRNA oligonucleotides on HIV-1 transduction and cDNA synthesis. HeLa cells were
transfected with the indicated siRNAs and challenged 72 hrs later with HIV-1NL4-3GFP reporter virus. (A). Cell lysate was probed in western blots
with anti-TNPO3 antibody (upper panel) and anti-b-actin antibody (lower panel). (B) HIV-1NL4-3GFP reporter gene expression was checked by
flow cytometry 72 hrs after virus challenge. 24 hrs after challenge with HIV-1NL4-3GFP, cell-associated DNA was harvested and processed by qPCR
for late RT (C), 2-LTR circles (D) and provirus (E). Azidothymidine (AZT) and Raltegravir (RAL) were used to block de novo reverse transcription
and integration, respectively. Data represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
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Page 11 of 19Figure 8 Effect of TNPO3 KD on HIV-1 infection of CD4
+ T cells.J u r k a tTc e l l s ,m o d i f i e dw i t hT N P O 3K Do rc o n t r o lK Dl e n t i v i r u s e s ,w e r e
challenged with WT or CA mutant HIV-1 viral vectors, as indicated. (A) GFP reporter gene expression was checked by flow cytometry 72 hrs
after HIV-1 challenge. Late RT (B), 2-LTR circles (C) and provirus (D) were assayed by qPCR 24 hrs after infection. Viruses bearing the enzymatic
site mutants RT-D185K/D186L or IN-D116A IN were used as controls for de novo reverse transcription and integration, respectively. Data
represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
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Page 12 of 19compared to WT virus, to nearly 10-fold. N74D and
A105T were not inhibited by TNPO3 KD in Jurkat T
cells (Figure 8A).
The early steps of HIV-1 infection in TNPO3 KD Jur-
kat cells were then characterized using the qPCR
method described in Figure 5. Jurkat T cells were chal-
lenged for 24 hrs with WT or CA mutant viruses and
DNA was extracted. Each sample was then subjected to
qPCR to assess the amount of late RT products (Figure
8B), 2-LTR circles (Figure 8C), and proviral DNA (Fig-
ure 8D). RT and IN mutant viruses were used as con-
trols for the qPCR reactions.
TNPO3 KD in Jurkat cells had no effect on the
amount of full-length viral cDNA produced by WT or
CA mutant viruses (Figure 8B). Similarly, no significant
effect was detected in the amount of 2-LTR circles pro-
duced by WT or CA mutant viruses infecting Jurkat
depleted of TNPO3 (Figure 8C). IN mutant D116A
showed a 2-fold increase in the amount of 2-LTR circles
synthesized. Finally, TNPO3 depletion blocked integra-
tion of WT and P90A/A92E mutant viruses, with a
magnitude of defect similar to that of the block in infec-
tivity (Figure 8D).
Discussion
CA determines HIV-1 dependence on TNPO3
A previous study demonstrated that CA, and not IN, is
the viral determinant of TNPO3-dependence, at least
when these components of HIV-1 were exchanged with
those of the TNPO3-independent virus MLV [33].
Though the results of that study were clear, interpreta-
tion was complicated by the fact that HIV-1/MLV chi-
meras are severely attenuated in terms of absolute
infectivity. Subsequent studies identified individual CA
residues that confer TNPO3-independence to HIV-1
[6,34]. Now we show that TNPO3 KD caused less than
2-fold reduction in infectivity for 18 CA mutants,
among which five had normal absolute infectivity. Addi-
tionally, two CA mutants were identified that are hyper-
sensitive to TNPO3 KD. From the analysis of 27 CA
mutants presented here, then, the importance of CA for
HIV-1 dependence on TNPO3 is unequivocal. While
our studies do not directly address the importance of IN
for TNPO3-dependence, one would need to invoke a
rather complex model to reconcile the data reported
here with one in which HIV-1 IN function requires
TNPO3.
CA mutants, CA lattice stability, and host factors
A significant fraction of the TNPO3-independent CA
mutants have been reported previously to have effects
on CA stability [4,44-46]. Amino acids E45, T54, N57,
Q63, Q67, K70, K140 and K182 are all located at the
interface between CA dimers in the CA lattice (Figure
3B). It is easy to imagine how changes in these positions
would alter contact between CA monomers, resulting in
a CA lattice with decreased stability. This would also
explain the decreased absolute infectivity of these
mutants (Figure 3A).
Among the TNPO3-independent mutants, N74 and
A105 localize to a pocket on the CA surface that is near
the dimer interface. This pocket is the target of a drug
t h a td e s t a b i l i z e st h eC Ac o r e[ 4 7 ] .T h eN 7 4 Da n d
A105T mutants might also decrease core stability, like
the CA mutants at the dimer interface, but to our
knowledge this has not been demonstrated. Given that
the absolute infectivity of N74D and A105T is normal,
it seems unlikely that the major effect of these mutants
would be to decrease core stability.
Mutants N74D and A105T might perturb binding to
the CA pocket of a cellular factor that alters CA stabi-
lity. TNPO3 itself has been reported to bind to CA [34]
and it potentially destabilizes the capsid lattice to facili-
tate uncoating. Alternatively, TNPO3 might regulate
another cellular factor that binds to CA. A good candi-
date for this putative factor would be cleavage and poly-
adenylation factor 6 (CPSF6), an SR-protein involved in
the processing of mRNA [51]. A C-terminal truncated
form of CPSF6 (CPSF6-358) inhibits HIV-1 infection
and the TNPO3-independent CA mutant viruses N74D,
Q63A/Q67A and E45A are resistant to CPSF6-358
restriction [6]. TNPO3 is a b-karyopherin that mediates
nuclear import of SR-proteins. The CPSF6-358 trunca-
tion removes the SR-rich domain, suggesting that
TNPO3 regulates HIV-1 by controlling CPSF6 localiza-
tion. How CPSF6-358 would inhibit HIV-1 infection is
unclear, but it might inhibit the virus by altering CA
stability.
CypA, a peptidylprolyl isomerase that directly binds
HIV-1 CA [52], also seems to act on the stability of the
CA core during HIV-1 infection [52,53]. In fact, the
CsA-dependent CA mutant A92E has decreased core
stability, which is restored if CA-CypA binding is
blocked [53]. The TNPO3-independent CA mutant
A105T rescues a conditional infectivity defect of the
A92E CA mutant virus [41], without altering the bind-
i n go fC At oC y p A( D eI a c oa n dL u b a n ,u n p u b l i s h e d
data).
The effect of TNPO3 on HIV-1 is first detectable after the
viral cDNA enters the nucleus
Since TNPO3 is a karyopherin that binds HIV-1 IN,
most studies have attempted to demonstrate a role for
TNPO3 in nuclear import of the HIV-1 PIC. Some of
them have been able to show it, some others not
[26,28,29,34,35]. As a result of this controversy, we
examined the role of TNPO3 in detail, using a range of
methodologies. As part of this analysis we developed
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reporter virus in cells that had already been transduced
with KD and rescue lentiviral vectors; this new assay
w i l lp r o v et ob ev a l u a b l ef o rf u t u r es t u d i e so fh o s tf a c -
tors of importance to HIV-1.
U s i n gar a n g eo fa p p r o a c h e sw ed e m o n s t r a t e dt h a t
TNPO3 has no detectable effect on the amount of 2-
LTR circles produced during HIV-1 infection. Given the
limitations of this indirect assay for nuclear import of
the PIC, our results suggest that TNPO3 acts on HIV-1
after the PIC arrives in the nucleus. It remains a possibi-
lity, though, that TNPO3 acts in the cytoplasm to pro-
mote maturation of the PIC via some unknown
mechanism. One group reported that TNPO3 is
required for nuclear import of PICs that were visualized
directly by GFP-labeled IN [28] but the functional sig-
nificance of these labeled complexes has not been
established.
According to generally accepted models of the HIV-1
replication cycle, HIV-1 CA uncoats in the cytoplasm to
permit reverse transcription, or perhaps uncoats in
response to reverse transcription [1]. Given our conclu-
sion that TNPO3 acts in the nucleus to promote HIV-1
infectivity, how would this fact be reconciled with the
importance of CA stability and uncoating for TNPO3-
dependence? It may be that some CA protein travels to
the nucleus with the PIC, and, as recently reported, that
TNPO3 promotes HIV-1 infection by stripping the resi-
dual CA associated with the PIC and exporting this
extracted CA to the cytosol [34]; this would free the
viral cDNA for more efficient integration.
Methods
Cell lines, tissue culture, and drugs
293T, TE671 and HeLa cells were grown in Dulbecco’s
modified Eagle medium (D-MEM) (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) (PAA), 20
mM L-glutamine, 1000 U/ml penicillin, and 1000 mg/ml
Streptomycin (GIBCO). Jurkat CD4
+ T cells were grown
in RPMI-1640 (Invitrogen) supplemented with 10% FBS.
Azidothymidine (AZT, NIBSC, UK) and Raltegravir
(RAL, Santa Cruz) were used at concentrations of 25
μM and 10 μM, respectively.
Plasmids
pWPTs-GFP is an HIV-1-based transfer vector with
EGFP expression under the control of the EF1a promo-
ter [54]. p8.9NdSB is a minimal HIV-1 packaging plas-
mid for gag and pol expression [55]. pMD2-G encodes
the vesicular stomatitis virus G protein (VSV-G) [56].
pNL4-3.GFP.E
- [57] bears HIV-1 proviral sequence with
an env-inactivating mutation and EGFP in place of nef.
pAPM is an HIV-1 based knockdown vector in which a
single transcript driven by the spleen focus-forming
virus (SFFV) LTR contains a miR30 framework modified
to target a gene of interest and the puromycin N-acetyl-
transferase gene [36]. pAIB is an HIV-1 based transfer
vector expressing the protein of interest from the SFFV
LTR followed by the encephalomyocarditis virus
(EMCV) internal ribosome entry site (IRES) cassette and
blasticidin-S-deaminase, drug resistance cassette [36].
pETSUMO-hTNPO3 bearing the human TNPO3 cDNA
was generously provided by Peter Cherepanov.
Knockdown Vector Cloning
Using the RNAi Central web-based shRNA design pro-
gram (http://cancan.cshl.edu/RNAi_central/RNAi.cgi?
type=shRNA - lab of Dr. Gregory Hannon, Cold Spring
Harbor Laboratory), we designed three miRNA-based
shRNA targeting sequences against the TNPO3 tran-
script. Three 97-mer oligonucleotides were synthesized
and PAGE purified: ts1, 5’-TGCTGTTGACAGTGAGC-
GACGCCAGAATCTGTGGACTCAATAGTGAAGC-
CACAGATGTATTGAGTCCACAGATTCTGGCGC
TGCCTACTGCCTCGGA-3’;t s 6 9 ,5 ’-TGCTGTTGA-
CAGTGAGCGCCCTCAATATGAGGTAGTAGAA-
TAGTGAAGCCACAGATGTATTCTACTACCTCA-
TATTGAGGATGCCTACTGCCTCGGA-3’; ts72, 5’-
TGCTGTTGACAGTGAGCGCGGACAGTAACTT-
CATGGCTAATAGTGAAGCCACAGATGTATTAGC-
CATGAAGTTACTGTCCATGCCTACTGCCTCGGA-
3’. The 97-mer oligonucleotides were then amplified by
PCR using the following primers: miR-30 XhoI 5’:5 ’-
AAGGCTCGAGAAGGTATATTGCTGTTGACAGT-
GAG-3’ and miR-30 EcoRI 3’:5 ’-AGCCCCTT-
GAATTCCGAGGCAGTAGGCA-3’. The PCR reaction
was carried out with AccuPrime Pfx SuperMix, 1 mol⁄L
Betaine(Sigma-Aldrich), 0.4 μmol⁄L each primer, and 100
ng 97-mer oligonucleotide template. The PCR product
was column purified, digested with XhoI and EcoRI, and
ligated in pAPM to create the pAPM-TNPO3 constructs
(ts1, ts69 and ts72). The function of TNPO3 KD vectors
(ts1, ts69 and ts72) was checked by generating stable,
puromycin-selected HeLa cells. Efficiency of the TNPO3
KDs was analyzed by looking at the expression levels of
TNPO3. Both ts69 and ts72 strongly inhibited the
expression of TNPO3, but ts72 was selected for most
experiments since of the three constructs it was the
most potent.
Mutagenesis
Overlapping PCR was used to generate mutations in the
CA, RT and IN coding sequences of p8.9NdSB using
the mutagenic oligonucleotides in Table 2.
For the CA mutants E45A, T54A, T54A/N57A, N57A,
Q63A/Q67A, K70R, N74D, G89V, G89V/A92E, P90A,
P90A/A92E, A92E, G94D and A105T, a PCR product of
957 bp was amplified using the external oligonucleotides
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Primer name Primer sequence
E45A fwd 5’-CAGCATTATCAGCTGGAGCCACCCC-3’
E45A rev 5’-GGGGTGGCTCCAGCTGATAATGCTG-3’
T54A fwd 5’-CCACAAGATTTAAACGCCATGCTAAACACAGTGG-3’
T54A rev 5’-CCACTGTGTTTAGCATGGCGTTTAAATCTTGTGG-3’
T54A/N57A fwd 5’- CCACAAGATTTAAACGCCATGCTAGCCACAGTGGGGGGAC-3’
T54A/N57A rev 5’-GTCCCCCCACTGTGGCTAGCATGGCGTTTAAATCTTGTGG-3’
N57A fwd 5’-CACCATGCTAGCCACAGTGGGGGGAC-3’
N57A rev 5’-GTCCCCCCACTGTGGCTAGCATGGTG-3’
Q63A/Q67A fwd 5’-GTGGGGGGACATGCAGCAGCCATGGCAATGTTAAAAGAGAC-3’
Q63A/Q67A rev 5’-GTCTCTTTTAACATTGCCATGGCTGCTGCATGTCCCCCCAC-3’
K70R fwd 5’-GCAGCCATGCAAATGTTAAGAGAGACCATCAATGAGGAAG-3’
K70R rev 5’-CTTCCTCATTGATGGTCTCTCTTAACATTTGCATGGCTGC-3’
N74D fwd 5’-GAGACCATCGATGAGGAAGCTGCAGAATGG-3’
N74D rev 5’-CCATTCTGCAGCTTCCTCATCGATGGTCTC-3’
G89V fwd 5’-CCAGTGCATGCAGTGCCTATTGCACCAGGCCAG-3’
G89V rev 5’-CTGGCCTGGTGCAATAGGCACTGCATGCACTGG-3’
G89V/A92E fwd 5’-CCAGTGCATGCAGTGCCAATTGAGCCAGGCCAGATGAG-3’
G89V/A92E rev 5’-CTCATCTGGCCTGGCTCAATTGGCACTGCATGCACTGG-3’
P90A fwd 5’-CCAGTGCATGCAGGTGCCATTGCACCAGGCCAGATG-3’
P90A rev 5’-CATCTGGCCTGGTGCAATGGCACCTGCATGCACTGG-3’
P90A/A92E fwd 5’-CCAGTGCATGCAGGCGCAATTGAGCCAGGCCAGATG-3’
P90A/A92E rev 5’-CATCTGGCCTGGCTCAATTGCGCCTGCATGCACTGG-3’
A92E fwd 5’-GTGCATGCAGGGCCAATTGAGCCAGGCCAGATG-3’
A92E rev 5’-CATCTGGCCTGGCTCAATTGGCCCTGCATGCAC-3’
G94D fwd 5’-GTGCATGCAGGGCCCATTGCACCAGACCAGATGAGAGAACC-3’
G94D rev 5’-GGTTCTCTCATCTGGTCTGGTGCAATGGGCCCTGCATGCAC-3’
A105T fwd 5’-GGAAGTGACATAACAGGAACTACTAGTACC-3’
A105T rev 5’-GGTACTAGTAGTTCCTGCTATGTCACTTCC-3’
K131R fwd 5’-CCAGTAGGAGAAATCTATAGAAGATGGATAATCCTGG-3’
K131R rev 5’-CCAGGATTATCCATCTTCTATAGATTTCTCCTACTGG-3’
R132K fwd 5’-GGAGAAATCTATAAAAAATGGATAATCCTGGG-3’
R132K rev 5’-CCCAGGATTATCCATTTTTTATAGATTTCTCC-3’
K140R fwd 5’-GGATAATCCTGGGATTAAATAGAATAGTAAGAATGTATAGC-3’
K140R rev 5’-GCTATACATTCTTACTATTCTATTTAATCCCAGGATTATCC-3’
K158R fwd 5’-GACATAAGACAAGGACCAAGGGAACCCTTTAGAGACTATG-3’
K158R rev 5’-CATAGTCTCTAAAGGGTTCCCTTGGTCCTTGTCTTATGTC-3’
K170R fwd 5’-CTATGTAGACCGATTCTATAGAACTCTAAGAGCCGAGC-3’
K170R rev 5’-GCTCGGCTCTTAGAGTTCTATAGAATCGGTCTACATAG-3’
K182R fwd 5’-CAAGCTTCACAAGAGGTAAGAAATTGGATGACAGAAACC-3’
K182R rev 5’-GGTTTCTGTCATCCAATTTCTTACCTCTTGTGAAGCTTG-3’
NotI fwd 5’-CCTTGGCTTCTTATGCGACGG-3’
SpeI rev 5’-GTCCAGAATGCTGGTAGGGC-3’
SpeI fwd 5’-GCTGCAGAATGGGATAGAGTGC-3’
ApaI rev 5’-GTGGGAAGGCCAGATCTTCC-3’
D185K/D186K fwd 5’-GACATAGTCATCTATCAATACATGAAGCTTTTGTATGTAGGATCTGACT TAG-3’
D185K/D186K rev 5’-CTAAGTCAGATCCTACATACAAAAGCTTCATGTATTGATAGATGACTA TGTC-3’
EcoRV fwd 5’-GTTCCCTTAGATAAAGACTTCAGG-3’
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were digested with NotI and SpeI and ligated to
p8.9NdSB cut with the same enzymes. For the CA
mutants K131R, R132K, K140R, K158R, K170R and
K182R, a PCR product of 499 bp was amplified using
the external oligonucleotides SpeI fwd and ApaI rev
(Table 2). The PCR products were digested with SpeI
and ApaI and ligated to p8.9NdSB cut with the same
enzymes. CA mutant V86P/H87Q/I91V/M96I was pre-
viously cloned [58].
For the RT mutant D185K/D186K a PCR product of
667 bp was amplified using the external oligonucleotides
EcoRV fwd and AgeI rev (Table 2). The PCR product
w a sd i g e s t e dw i t hE c o R Va n dA g e Ia n dl i g a t e dt o
p8.9NdSB cut with the same enzymes. For IN mutant
D116A a PCR product of 1767 bp was amplified using
the external oligonucleotides AgeI fwd and EcoRI rev
(Table 2). The PCR product was digested with AgeI and
EcoRI and ligated to p8.9NdSB cut with the same
enzymes. All mutations were confirmed by sequencing.
To render TNPO3 expression resistant to TNPO3 KD,
silent mutations were introduced into the TNPO3
cDNA by overlapping PCR using the oligonucleotides
ntTNPO3 fwd; ntTNPO3 rev (Table 2) This was cloned
into pAIB [36]. The ntTNPO3 sequence was then con-
firmed by DNA sequencing. The SFFV promoter driving
ntTNPO3 transcription in the pAIB vector was then
replaced with the CMVie promoter from pcDNA3.1- to
obtain a higher level of expression of TNPO3 expression
in HeLa cells. At the same time an HA-tag was intro-
duced at the N-terminus of the protein. The primers
used were CMV fwd and CMV rev (Table 2)
Production of viruses and vectors
Viruses and minimal vectors were produced by transfec-
tion of 293T cells using Polyethylenimine (PEI) (Sigma,
Inc). 4 × 10
6 cells per plate were seeded in 10 cm plates,
one day prior to transfection. The DNA for the transfec-
tion was mixed with 50 μl of PEI (1 mg/ml) in 1 ml of
DMEM without serum for 20 min at room temperature.
6 hrs after transfection the transfection medium was
replaced with fresh target-cell medium. 48 hrs after
transfection the supernatant was collected, centrifuged
at 1200 × rpm for 5 min, filtered through a sterile 0.45
μm syringe filter (Millipore), and stored in 1 mL ali-
quots at -80°C. When comparing viruses or vectors,
samples were normalized by RT activity present in the
viral supernatant using the PCR-based assay described
below. For three-part vector systems, the following DNA
ratio was used: 3 parts transfer vector: 2 parts packaging
plasmid: 1 part envelope. For two-part virus systems a
4:1 ratio was used (7 parts env
- virus: 1 part envelope)
Reverse transcriptase assay (SGPERT)
Reverse transcriptase (RT) activity in the supernatants
was quantified using a Sybr green I-based real-time PCR
enhanced RT assay (SGPER) that possesses both high
sensitivity and an extraordinary dynamic range. The
assay is a modified version of one described previously
[59]. Briefly, virions in cell-free supernatant were dis-
rupted by adding an equal volume of SGPERT lysis buf-
fer containing 0.25% Triton X-100, 50 mM KCl, 100
mM TrisHCl pH7.4, 0.4 U/μl RNase inhibitor (Ribo-
Lock, MBI Fermentas). Lysed virions were used for
reverse transcription of MS2 RNA template (Roche)
[60]. Quantification of reverse transcribed products was
carried out in a CFX96 thermal cycler (Biorad) using
Sybr-Green I, hotstart Taq and reaction buffer (Fermen-
tas), and an MS2 primer set as already described [60]. A
standard curve was obtained using known concentra-
tions (expressed in functional units) of recombinant
HIV-1 RT (Ambion).
Generation of TNPO3 KD cells and rescue of the TNPO3
protein
To generate stable microRNA-based shRNA KDs, HeLa
cells were transduced with pAPM microRNA-based
shRNA vectors [36] targeting either control or TNPO3
Table 2 Oligonucleotides used for cloning in this study. (Continued)
AgeI rev 5’-GATATGTCCATTGGCCTTGC-3’
D116A fwd 5’-CAGTAAAAACAGTACATACAGCCAATGGCAGCAATTTCACC-3’
D116A rev 5’-GGTGAAATTGCTGCCATTGGCTGTATGTACTGTTTTTACTG-3’
AgeI fwd 5’-CCAAAGCACTAACAGAAGTAGTACC-3’
EcoRI rev 5’-CGAGTAACGCCTATTCTGCTATG-3’
ntTNPO3 fwd 5’-GTTGGTTTAACTTGGGAGTTTTAGATTCGAATTTTATGGCTAACAATAA ATTACTAGCAC-3’
ntTNPO3 rev 5’-GTGCTAGTAATTTATTGTTAGCCATAAAATTCGAATCTAAAACTCCCAA GTTAAACCAAC-3’
AflII fwd 5’-TGTGTGCTTAAGCTCGAGTGGTGGCATGGAAGGAGCAAAGC-3’
KpnI rev 5-GTAAGCTTTGAAGATGCCATG-3’
CMV fwd 5’- TGTGTGTTAATTAAGCGTTGACATTGATTATTGACTAG-3’
CMV rev 5’- CACACACTCGAGCCCTTGTCATCGTCGTCCTTGTAGTCCATGTTTAAA CGCTAGCCAGCTTG-3’
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tion, the cells were selected with 10 μg⁄mL puromycin
dihydrochloride. To generate the TNPO3 rescue cells,
HeLa TNPO3 KD and control KD cells were transduced
with the pAIB-CMV expression vector, either empty or
encoding the ntTNPO3. 2 days after transduction, the
cells were selected with 10 μg⁄mL blasticidin for 3 days
and assayed for KD and protein rescue by SDS-PAGE⁄
western blot.
For transient siRNA, 100 nM of Gene Solution siRNA
(Qiagen) targeting TNPO3 was complexed with 5 μlo f
Lipofectamine RNAiMAX (Invitrogen), following the
manufacturer’s instruction, and added to the cells. KD
was assessed by SDS-PAGE/western blot 72 h after
transfection.
Quantitative PCR for viral cDNA
Total DNA was extracted from 4 × 10
6 cells using the
DNeasy Blood & Tissue Kit (Qiagen), following the
manufacturer’s instructions.
Quantitative PCR for pWPTs-GFP full-length linear
cDNA and 2-LTR circles were detected with Sybr green
(Invitrogen), while Alu-PCR used a TaqMan probe. The
primers used for the detection of late RT products were:
pWPT J1B fwd and pWPT J2 rev (Table 3). The primers
used for the detection of 2-LTR circles were: R2 fwd
and LoxP2 rev (Table 3). The primers used for the ana-
lysis of the proviruses were: pWPT J1B fwd, SB704 rev
and MH603 probe [50] (Table 3).
Late RT and 2-LTR circle PCR reaction mixes con-
tained 1× Sybr green mix (10 mM Tris pH 8.3, 10 mM
KCl, 2.5 mM NH4SO4, 5 mM MgCl2, 0.1 mg/ml BSA, 0.2
mM dNTPs, 1× Sybr green), 300 nM each primer, 100 to
200 ng of template DNA, and 1 μl of Hot Start Taq Poly-
merase (Promega) in a volume of 20 μl. Alu PCR reaction
mix contained 1× TaqMan Universal Master Mix
(Applied Biosystems), 50 nM pWPT J1B fwd primer, 900
nM SB704 rev primer, 100 nM MH603 probe and 100 to
200 ng of template DNA in a volume of 20 μl.
For late RT and 2-LTR circle analysis, after initial
incubation at 95°C for 2 min to activate the Hot Start
Taq Polymerase, 40 cycles of amplification and acquisi-
tion were carried out at 95°C for 6 s, followed by 10 s at
55°C, 30 s at 72°C and 6 s at 80°C. For Alu PCR, after
an initial incubation at 95°C for 10 min, 40 cycles of
amplification were carried out at 95°C for 15 s followed
by 1 min and 30 s at 60°C. qPCR reactions were made
using the CFX96™ thermal cycler (Biorad).
qPCR for NL4.3 GFP E- full-length linear cDNA, 2-
LTR circles and Alu PCR was performed as described
previously [50] (Table 4).
Where indicated, cells were treated with AZT or RAL,
1 hr before infection at concentrations of 25 μMa n d1 0
μM, respectively.
Western blot analysis
For western blot analysis we used rabbit anti-TNPO3
antibody (ab71388, abcam) and mouse anti-actin
Table 3 Oligonucleotides used for pWPTs-GFP quantitative PCR.
Primer name Primer sequence
Late RT pWPT J1B fwd 5’-GCATACATTATACGAAGTTATGCTGC-3’
pWPT J2 rev 5’-GCCGTGCGCGCTTCAGCAAGC-3’
2-LTR R2 fwd 5’-TGGGAGCTCTCTGGCTAACTAG-3’
LoxP2 rev 5’-GTGAATTGATCCCATCTTGTC-3’
Alu PCR pWPT J1B fwd 5’-GCATACATTATACGAAGTTATGCTGC-3’
SB704 rev 5’-TGCTGGGATTACAGGCGTGAG-3’
MH603 probe 5’-(FAM)-ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAMRA)-3’
Table 4 Oligonucleotides used for NL4.3 GFP E- quantitative PCR (Butler 2001).
Primer name Primer sequence
Late RT MH531 5’-GCATACATTATACGAAGTTATGCTGC-3’
MH532 5’-GCCGTGCGCGCTTCAGCAAGC-3’
LRT-P 5’-(FAM)-CAGTGGCGCCCGAACAGGGA-(TAMRA)-3’
2-LTR MH535 5’-AACTAGGGAACCCACTGCTTAAG-3’
MH536 5’-TCCACAGATCAAGGATATCTTGTC-3’
MH603 probe 5’-(FAM)-ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAMRA)-3’
Alu PCR MH535 5’-AACTAGGGAACCCACTGCTTAAG-3’
SB704 rev 5’-TGCTGGGATTACAGGCGTGAG-3’
MH603 probe 5’-(FAM)-ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAMRA)-3’
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linked donkey anti-rabbit IgG and HRP-linked sheep
anti-mouse IgG (GE Healthcare Life Sciences).
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